CEFTIN
LOE ApproachingNDAORALFOR SUSPENSION
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFTIN is an oral cephalosporin antibiotic approved in 1994 for treating bacterial infections. The generic name is cefuroxime axetil, a second-generation cephalosporin that inhibits bacterial cell wall synthesis. It is used for respiratory tract, urinary tract, Lyme disease, and other systemic infections across diverse patient populations.
LOE Approaching
Moderate competitive pressure (30/100) signals a mature, stable market with limited growth; teams are typically lean and focused on retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEFTIN offers limited career growth due to its mature, LOE-approaching status and zero linked job postings. Roles available are primarily in operational management, defensive marketing, and compliance rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on CEFTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.